Study finds rising incidence and cancer risk in US systemic mastocytosis cases
New study reveals rising U.S. rates of systemic mastocytosis and increased risk of secondary cancers, especially in older adults.
New study reveals rising U.S. rates of systemic mastocytosis and increased risk of secondary cancers, especially in older adults.
Relying on BST levels to diagnose SM doesn’t account for individual variability influenced by genetic and physiological factors.
Several newly approved and experimental treatments have shown promise in the management of systemic mastocytosis.
A genetic trait that increases risk of anaphylaxis is higher in people with SM. Identifying the trait early could mean better treatment.
The targeted therapy drug gemtuzumab ozogamicin successfully treated a young boy with SM-AHN who did not respond to conventional therapies.
As fire ants spread to more areas, people with SM face a greater risk of severe allergic reactions from fire ant stings.
Avapritinib treatment improves survival outcomes and symptom management in patients with SM, its maker reported.